Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Bottom Line: The associated cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid.The effects on growth plate cartilage were visualised by toluidine blue staining.The number of circulating tumour cells was reduced in ZOL treated animals.
Affiliation: CR-UK/YCR Cancer Research Centre, University of Sheffield, Sheffield, UK. Electronic address: firstname.lastname@example.org.Show MeSH
Related in: MedlinePlus
Mentions: ZOL caused a significant increase in trabecular bone volume of proximal tibias from day 3 onwards when compared to control animals (PBS: 15.67% vs. ZOL: 18.92%; p ≤ 0.01; Fig. 2A). This increase was less prominent on day 5 but remained significantly elevated at day 10 (PBS: 15.35% vs. ZOL: 20.88%; p ≤ 0.0001; Fig. 2A). ZOL also significantly increased trabecular number by day 10 (PBS: 3.27 mm− 1 vs. ZOL: 4.45 mm− 1; p ≤ 0.01; Fig. 2B) when compared to PBS treatment. Representative cross sections of the proximal tibia illustrating this effect are shown in Fig. 2C.
Affiliation: CR-UK/YCR Cancer Research Centre, University of Sheffield, Sheffield, UK. Electronic address: email@example.com.